Response of chronic cough to acid-suppressive therapy in patients with gastroesophageal reflux disease

Peter J. Kahrilas, Colin Howden, Nesta Hughes, Michael Molloy-Bland

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Background: Epidemiologic and physiologic studies suggest an association between gastroesophageal reflux disease (GERD) and chronic cough. However, the benefit of antireflux therapy for chronic cough remains unclear, with most relevant trials reporting negative findings. This systematic review aimed to reevaluate the response of chronic cough to antireflux therapy in trials that allowed us to distinguish patients with or without objective evidence of GERD. Methods: PubMed and Embase systematic searches identified clinical trials reporting cough response to antireflux therapy. Datasets were derived from trials that used pH-metry to characterize patients with chronic cough. Results: Nine randomized controlled trials of varied design that treated patients with acid suppression were identified (eight used proton pump inhibitors [PPIs], one used ranitidine). Datasets from two crossover studies showed that PPIs significantly improved cough relative to placebo, albeit only in the arm receiving placebo first. Therapeutic gain in seven datasets was greater in patients with pathologic esophageal acid exposure (range, 12.5%-35.8%) than in those without (range, 0.0%-8.6%), with no overlap between groups. Conclusions: A therapeutic benefit for acid-suppressive therapy in patients with chronic cough cannot be dismissed. However, evidence suggests that rigorous patient selection is necessary to identify patient populations likely to be responsive, using physiologically timed cough events during reflux testing, minimal patient exclusion because of presumptive alternative diagnoses, and appropriate power to detect a modest therapeutic gain. Only then can we hope to resolve this vexing clinical management problem.

Original languageEnglish (US)
Pages (from-to)605-612
Number of pages8
JournalChest
Volume143
Issue number3
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Gastroesophageal Reflux
Cough
Acids
Proton Pump Inhibitors
Therapeutics
Placebos
Ranitidine
PubMed
Cross-Over Studies
Patient Selection
Epidemiologic Studies
Randomized Controlled Trials
Clinical Trials
Population
Datasets

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Response of chronic cough to acid-suppressive therapy in patients with gastroesophageal reflux disease. / Kahrilas, Peter J.; Howden, Colin; Hughes, Nesta; Molloy-Bland, Michael.

In: Chest, Vol. 143, No. 3, 01.01.2013, p. 605-612.

Research output: Contribution to journalArticle

Kahrilas, Peter J. ; Howden, Colin ; Hughes, Nesta ; Molloy-Bland, Michael. / Response of chronic cough to acid-suppressive therapy in patients with gastroesophageal reflux disease. In: Chest. 2013 ; Vol. 143, No. 3. pp. 605-612.
@article{3797916dc50a4bdda1dfca24c1879851,
title = "Response of chronic cough to acid-suppressive therapy in patients with gastroesophageal reflux disease",
abstract = "Background: Epidemiologic and physiologic studies suggest an association between gastroesophageal reflux disease (GERD) and chronic cough. However, the benefit of antireflux therapy for chronic cough remains unclear, with most relevant trials reporting negative findings. This systematic review aimed to reevaluate the response of chronic cough to antireflux therapy in trials that allowed us to distinguish patients with or without objective evidence of GERD. Methods: PubMed and Embase systematic searches identified clinical trials reporting cough response to antireflux therapy. Datasets were derived from trials that used pH-metry to characterize patients with chronic cough. Results: Nine randomized controlled trials of varied design that treated patients with acid suppression were identified (eight used proton pump inhibitors [PPIs], one used ranitidine). Datasets from two crossover studies showed that PPIs significantly improved cough relative to placebo, albeit only in the arm receiving placebo first. Therapeutic gain in seven datasets was greater in patients with pathologic esophageal acid exposure (range, 12.5{\%}-35.8{\%}) than in those without (range, 0.0{\%}-8.6{\%}), with no overlap between groups. Conclusions: A therapeutic benefit for acid-suppressive therapy in patients with chronic cough cannot be dismissed. However, evidence suggests that rigorous patient selection is necessary to identify patient populations likely to be responsive, using physiologically timed cough events during reflux testing, minimal patient exclusion because of presumptive alternative diagnoses, and appropriate power to detect a modest therapeutic gain. Only then can we hope to resolve this vexing clinical management problem.",
author = "Kahrilas, {Peter J.} and Colin Howden and Nesta Hughes and Michael Molloy-Bland",
year = "2013",
month = "1",
day = "1",
doi = "10.1378/chest.12-1788",
language = "English (US)",
volume = "143",
pages = "605--612",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",

}

TY - JOUR

T1 - Response of chronic cough to acid-suppressive therapy in patients with gastroesophageal reflux disease

AU - Kahrilas, Peter J.

AU - Howden, Colin

AU - Hughes, Nesta

AU - Molloy-Bland, Michael

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background: Epidemiologic and physiologic studies suggest an association between gastroesophageal reflux disease (GERD) and chronic cough. However, the benefit of antireflux therapy for chronic cough remains unclear, with most relevant trials reporting negative findings. This systematic review aimed to reevaluate the response of chronic cough to antireflux therapy in trials that allowed us to distinguish patients with or without objective evidence of GERD. Methods: PubMed and Embase systematic searches identified clinical trials reporting cough response to antireflux therapy. Datasets were derived from trials that used pH-metry to characterize patients with chronic cough. Results: Nine randomized controlled trials of varied design that treated patients with acid suppression were identified (eight used proton pump inhibitors [PPIs], one used ranitidine). Datasets from two crossover studies showed that PPIs significantly improved cough relative to placebo, albeit only in the arm receiving placebo first. Therapeutic gain in seven datasets was greater in patients with pathologic esophageal acid exposure (range, 12.5%-35.8%) than in those without (range, 0.0%-8.6%), with no overlap between groups. Conclusions: A therapeutic benefit for acid-suppressive therapy in patients with chronic cough cannot be dismissed. However, evidence suggests that rigorous patient selection is necessary to identify patient populations likely to be responsive, using physiologically timed cough events during reflux testing, minimal patient exclusion because of presumptive alternative diagnoses, and appropriate power to detect a modest therapeutic gain. Only then can we hope to resolve this vexing clinical management problem.

AB - Background: Epidemiologic and physiologic studies suggest an association between gastroesophageal reflux disease (GERD) and chronic cough. However, the benefit of antireflux therapy for chronic cough remains unclear, with most relevant trials reporting negative findings. This systematic review aimed to reevaluate the response of chronic cough to antireflux therapy in trials that allowed us to distinguish patients with or without objective evidence of GERD. Methods: PubMed and Embase systematic searches identified clinical trials reporting cough response to antireflux therapy. Datasets were derived from trials that used pH-metry to characterize patients with chronic cough. Results: Nine randomized controlled trials of varied design that treated patients with acid suppression were identified (eight used proton pump inhibitors [PPIs], one used ranitidine). Datasets from two crossover studies showed that PPIs significantly improved cough relative to placebo, albeit only in the arm receiving placebo first. Therapeutic gain in seven datasets was greater in patients with pathologic esophageal acid exposure (range, 12.5%-35.8%) than in those without (range, 0.0%-8.6%), with no overlap between groups. Conclusions: A therapeutic benefit for acid-suppressive therapy in patients with chronic cough cannot be dismissed. However, evidence suggests that rigorous patient selection is necessary to identify patient populations likely to be responsive, using physiologically timed cough events during reflux testing, minimal patient exclusion because of presumptive alternative diagnoses, and appropriate power to detect a modest therapeutic gain. Only then can we hope to resolve this vexing clinical management problem.

UR - http://www.scopus.com/inward/record.url?scp=84874988848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874988848&partnerID=8YFLogxK

U2 - 10.1378/chest.12-1788

DO - 10.1378/chest.12-1788

M3 - Article

VL - 143

SP - 605

EP - 612

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -